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Background: Mozambique presents a very high prevalence of both malaria and HIV infection, but the impact of
co-cancel infection on morbidity in this population has been rarely investigated. The aim of this study was to
describe the prevalence and clinical characteristics of malaria in hospitalized adult HIV-positive patients, treated and
untreated with combination anti-retroviral therapy (ART) and cotrimoxazole (CTX)-based chemoprophylaxis,
compared to HIV negatives.
Methods: From November to December 2010, all adult patients consecutively admitted to the Department of
Internal Medicine of Beira Central Hospital, Sofala Province, Mozambique, were submitted to HIV testing, malaria
blood smear (MBS) and, in a subgroup of patients, also to the rapid malaria test (RDT). Socio-demographical and
clinical data were collected for all patients. The association of both a positive MBS and/or RDT and diagnosis of
clinical malaria with concomitant HIV infection (and use of CTX and/or ART) was assessed statistically. Frequency of
symptoms and hematological alterations in HIV patients with clinical malaria compared to HIV negatives was also
analysed. Sensitivity and specificity for RDT versus MBS were calculated for both HIV-positive and negative patients.
Results: A total of 330 patients with available HIV test and MBS were included in the analysis, 220 of whom (66.7%)
were HIV-positive. In 93 patients, malaria infection was documented by MBS and/or RDT. RDT sensitivity and
specificity were 94% and 96%, respectively. According to laboratory results, the initial malaria suspicion was
discarded in about 10% of cases, with no differences between HIV-positive and negative patients. A lower malaria
risk was significantly associated with CTX prophylaxis (p=0.02), but not with ART based on non nucleoside
reverse-transcriptase inhibitors (NNRTIs). Overall, severe malaria seemed to be more common in HIV-positive
patients (61.7%) compared to HIV-negatives (47.2%), while a significantly lower haemoglobin level was observed in
the group of HIV-positive patients (9.9±2.8mg/dl) compared to those HIV-negative (12.1±2.8mg/dl) (p=0.003).
Conclusions: Malaria infection was rare in HIV-positive individuals treated with CTX for opportunistic infections,
while no independent anti-malarial effect for NNRTIs was noted. When HIV and malaria co-infection occurred, a
high risk of complications, particularly anaemia, should be expected.
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Since 2009, the CDC has included malaria in the list of
AIDS-related opportunistic infections [1]; even though
malaria is not among the leading causes of death in
HIV-infected patients [2], it has been identified as the
third most important source of HIV-related morbidity in
Africa [3]. In fact, HIV infection is expected to increase
the morbidity and mortality attributed to malaria, since
immuno suppression impairs the immune response to
Plasmodium, determining more frequent occurrences of
clinically severe malaria [4]. However, the use of cotri-
moxazole (CTX) prophylaxis and antiretroviral therapy
(ART) in HIV-infected patients seems to provide a pro-
tective effect from malaria [4-6].
In Mozambique, all regions show a very high preva-
lence of both malaria and HIV infections, particularly
Beira (Sofala province), which is a historically important
harbour on the Indian ocean, situated at the beginning of
the commercial route to Zimbabwe and central Africa. In
fact, HIV prevalence is approximately estimated at 30%
in the urban area of Beira [7,8], while malaria transmis-
sion is stable throughout the country with peaks from
December to April. Plasmodium falciparum accounts for
>95% of cases at a rate of about 200 per 1,000 inhabi-
tants (all ages) in 2009. While coverage with an artemisin-
based combination therapy (artemether-lumefantrine),
adopted in 2004, is adequate, the distributionof insecticide-
treated nets and indoor residual spraying have remained
low (43% and 37%, respectively, in 2009) [9]. On the
other hand, the introduction of ART in Mozambique
initiated in 2004, has reached a coverage of around 40%
for patients with a CD4 level<200 cells/mmc in 2008
according to UNAIDS estimations [8]. Therefore, the real
impact of therapy implementation, along with the use of
CTX-based prophylaxis on mortality and morbidity due
to AIDS-related opportunistic infections, including mal-
aria, still needs to be fully evaluated.
Moreover, the frequent overlap between clinical signs
and symptoms of HIV and malaria, especially regarding
fever and anaemia, can determine many difficulties for
diagnosis. A previous study in Mozambique [10] demon-
strated a statistically significant association between HIV
status and risk of receiving an incorrect malaria diagno-
sis. In fact, according to recent WHO guidelines, the
confirmation of diagnosis by microscopy (malaria blood
smear, MBS) or rapid diagnostic tests (RDTs) is recom-
mended for all patients with suspected malaria before
treatment is initiated, but presumptive treatment is still
a common practice in malaria-endemic resource-limited
settings. According to the last WHO report (2010) re-
garding malaria in Mozambique, only 13% of cases were
confirmed by microscopy and/or RDT [9].
The aim of this study was to describe the preva-
lence and clinical characteristics of malaria infection inhospitalized adult HIV-positive patients treated and un-
treated with ART and CTX, compared to HIV-negatives.
Methods
From November to December 2010, all adult patients
(> 15 years, according to the hospital policy) consecu-
tively admitted to the Department of Internal Medicine
of the Beira Central Hospital, Sofala, Mozambique were
enrolled in the study.
The main objective of the study was to verify the asso-
ciation of a malaria infection with the contemporary
presence of HIV infection, treated or untreated by CTX
and ART. For this purpose, all patients with a positive
malaria blood slide (MBS) and/or rapid diagnostic test
(RDT) were considered as infected with malaria.
The secondary objectives were:
– to evaluate the accuracy of RDT in both HIV-negative
and positive patients
– to compare the frequency and severity of clinical
symptoms and the hematological alterations in patients
with concurrent clinical malaria and HIV with respect
to HIV seronegatives. Patients for whom, despite a
positive malaria test, a diagnosis of clinical malaria was
considered not plausible by clinicians based on clinical
history (absence of fever at admission or in the
previous 24 hours and/or evidence of symptoms and
signs, e.g. neck stiffness, suggestive of other diagnoses
and confirmed by microbiological and/or histological
data) were excluded from this sub-analysis.
According to the hospital policy, voluntary counseling
and testing for HIV was offered to all admitted patients
by a trained nurse, and performed in all cases of accept-
ance, with the exception of those who were already
ascertained HIV-positive. HIV tests were performed with
both the Determine (Abbot Japan co, Ltd) and Unigold
tests (Trinity Biotech plc, Bray, Ireland).
During the study period for purposes of analysis, a
malaria blood slide (MBS) was obtained from all patients
consecutively hospitalized in Internal medicine, even in
the absence of highly suspicious symptoms such as fever.
malaria slides were prepared and evaluated as part of the
hospital routine. Parasitaemia was assessed using a semi-
quantitative method providing a score as follows: 1
(+=1–10 parasites per 100 fields); 2 ( ++=11–100 para-
sites per 100 fields); 3 (+++=1–10 parasites per 1 field );
4 (++++=more than 10 parasites per field). A RDT (Mal-
aria P.F. HRP II Ag rapid test, Orchid Biomedical Sys-
tems,goa, India) was also performed in a subgroup of
160 cases, consecutively enrolled during the first month
of the study period.
Socio-demographical and clinical data were collected
by two fifth-year medical students from the Catholic
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of the researchers and attending clinicians. Information
included the diagnosis at admission formulated by the
first visiting medical physician, the main symptom/signs
referred at time of admission based on data obtained by
questions to patients and on direct clinical examination.
The available blood parameters included white blood
cell count (number/mmc), platelet count (number x
100 000/mmc) and haemoglobin (mg/dl). Blood glucose
level (mmol/L) was available only in a minority of cases.
The results of HIV and malaria testing were recorded for
all patients. For the HIV-positive patients, the date of the
first positive anti-HIV test, the use of CTX as chemo-
prophylaxis for opportunistic infections, and the use and
date of ART initiation were also reported. The CD4 cell
count was available only in a minority of patients and was
not considered in the analysis. HIV-RNA measurement
was not available in the hospital at time of study.
Based on available laboratory parameters, clinical mal-
aria was classified as complicated or severe according to
the presence of neurological symptoms (impaired con-
sciousness or multiple convulsions), severe dyspnea or
radiological signs of pulmonary edema, hypotension (sys-
tolic pressure<70mmhg), severe anaemia (<5mg/dl), se-
vere jaundice, spontaneous bleeding, haemoglobinuria,
oliguria and,whenavailable,hypoglycaemia(<2.5mmol/L).
Parasitaemia was not included among the parameters
as only a semi quantitative method was furnished by
the laboratory.
The study was approved by the Ethical Committee of
the Beira Central Hospital. Data were obtained in the
context of normal clinical routines. However, all patients
provided oral informed consent for the use of their data
for research purposes. For unconscious patients, the
family members were asked to give consent.Statistical analysis
Descriptive statistics were produced for the demographic
and clinical characteristics of all cases. The mean and
SD are presented for normally distributed variables. The
Student t test (Kruskal-Wallis rank sum test or mann–
Whitney median test for skewed distributions) was usedTable 1 Patient characteristics
HIV
Total Positive Negati
No. patients (%) 330 (100%) 220 (66.7%) 110 (33.
Gender Female 168 (50.9%) 111 (50,5%) 57 (51.8
Age (years,mean±SD) 38±15 35±11 43±1
HIV known 104 (47.3%) -
CTX prophylaxis 78 (35.4%) -
ART 69 (31.4) -to compare quantitative variables, and the Pearson chi
square test (Fisher exact test where appropriate) was
used for categorical variables. Univariate and multivari-
ate analysis by means of logistic regression were carried
out to investigate variables associated with a positive
malaria test. A p value<0.05 was considered statistically
significant. All analyses were performed with EpiInfo
software, version 3.5.3 (CDC, Atlanta).Results
A total of 342 adult patients admitted to the Department
of Internal medicine of the Beira Central Hospital
were enrolled in the study, 330 of whom (mean age
of 38±15years, 50.9% females) had an available HIV test
and malaria blood slide and were included in the ana-
lysis. Twelve patients refused to be submitted to HIV
testing and were excluded from the study; the demo-
graphic and clinical characteristics of these patients did
not significantly differ from those of the included
patients (data not shown). The characteristics of
patients enrolled in the study according to the results of
HIV and malaria testing are summarized in Table 1.
A total of 220/330 (66.7%) enrolled patients resulted
HIV-positive, but only 104/220 (47.3%) were already
aware of their HIV-seropositivity before admission; in
the remaining 116 cases, diagnosis of HIV infection was
performed for the first time during hospitalization. HIV-
positive patients were equally distributed for gender
(50.4% females), while the mean age was significantly
lower among HIV-infected patients compared to HIV-
negatives (35.5±11.9 versus 43.4±19.5, respectively;
p=0.002). A WHO stage III-IV was presented by 77%
(140/182 available) of patients.
Daily CTX chemoprophylaxis was being administered
to 78/220 (35.4%) HIV-positive patients at time of ad-
mission, while only 69 patients (31.4%) were assuming
antiretroviral therapy, 55 of whom were concurrently re-
ceiving CTX. All patients, except two, were treated by
an ART based on NNRTIs (nevirapine in 63 cases and
efavirenz in 4 cases); the NRTI backbone was composed
of a stavudine and lamivudine combination in 42 patients
and by zidovudine and lamivudine in the remaining 12.Malaria
ve p value Positive Negative p value
3%) 93 (28.2%) 237 (71.8%)
%) 0.4 68 (73.1%) 100 (42.2%) <0.001
9 0.002 34±14 40±15 0.001
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men represented by two previously unused NRTIs and
lopinavir/ritonavir. The median duration of ART was
four months (range 1–48).
Among the 330 patients consecutively subjected to a
malaria blood slide, 90 (27.3%) resulted positive. In a
subgroup of 160 patients, consecutively admitted, a rapid
diagnostic test for malaria was also performed resulting
in 50 positives; discordant results were obtained in only
seven patients, three of whom presented a positive RDT
despite a negative blood slide, while RDT yielded nega-
tive results despite a positive MBS in four patients.
Therefore, when considering the blood slide as a gold
standard, the RDT sensitivity was 94% with a specificity
of 96%, with no remarkable differences between the two
groups of HIV-positive and negative patients. The group
of patients with a malaria infection included a higher
number of females (68/93, 73.1%, p<0.001) and younger
patients (mean age 34.3±14.2 versus 39.6±15.5 in
malaria-negatives, p=0.001). For purposes of analysis, all
patients (n=93) presenting a positive MBS and/or RDT
were considered as infected with malaria parasites.
Clinicians had previously indicated malaria as the
main reason for hospital admission in a total of
86/330 cases (26.1%). When data were retrospectively
analysed according to results of HIV testing, it was ob-
served that malaria appeared to be the most frequently
presumed reason (33.6%) for admission in the group of
HIV-negative patients, while clinical suspicion of tu-
berculosis was the main reason for admission in the
group of HIV-positive patients (32.3%), followed by mal-
aria in 22.6% of cases. The hypothesis of malaria was
rejected, based on laboratory results, in 9/86 (10.5%)
patients for whom a clinical suspicion had been raised,
6/49 (12%) of whom resulted HIV-positive and 3/37Table 2 Univariate and multivariate analysis of factors influen
slide and/or rapid diagnostic test, n=93)
Univariate analysis
Gender (M vs F)
Age (≥35 vs<35)
HIV infection (yes vs no)
Cotrimoxazole prophylaxis (yes vs no)
Antiretroviral treatment (yes vs no)
Multivariate analysis
Gender (M vs F)
Age (≥35vs<35)
HIV infection (yes vs no)
Cotrimoxazole prophylaxis (yes vs no)
Antiretroviral treatment (yes vs no)(8.1%) HIV-negative, without any difference between the
two groups (p=0.7).
Overall, the frequency of a positive malaria test was
slightly lower among HIV-positives compared to HIV-
negative patients (25.9% versus 32.7%, respectively), with-
out any statistically significant difference. The diagnosis of
malaria was significantly less likely in the group of patients
assuming a daily cotrimoxazole chemoprophylactic regi-
men compared to those without prophylaxis (12.8% versus
32.9%, respectively, p<0.001) and in patients assuming
ART compared to untreated patients (17.4% versus 29.8%,
respectively, p=0.03). At multivariate analysis, however,
only CTX prophylaxis (p=0.02), together with age
≥35years (p=0.004) and male gender (p<0.001), were in-
dependently associated with a lower risk of malaria infec-
tion (Table 2).
The level of parasitaemia was slightly lower in HIV-
positive versus HIV-negative patients (mean 1.8±1.1 ver-
sus 2.3±1.2, respectively, p=0.08), but when patients on
CTX and/or ART were excluded, no significant dif-
ferences were observed between the two groups (mean
2.3±1.2 versus 2.0±1.2, respectively, p=0.2).
Based on patient history and clinical examination, clin-
ical malaria was excluded for 10/93 patients with a posi-
tive malaria test, six of whom because of complete
absence of fever and four because of a diagnosis of bacter-
ial meningitis, suspected on the basis of neck stiffness and
ascertained by liquor examination after rachicentesis.
These excluded ten patients presented a positive mBS
with low grade parasitemia (only one cross positivity in
four cases and two crosses in the additional four patients),
which was assumed to be premunity, without relevance
for the patient’s clinical condition at time of admission;
another two patients were RDT positive/slide negative.
Regarding distribution of clinical malaria, a highercing probability of positive malaria test (malaria blood
OR (95% I.C.) p value
0.27 (0.16-0.45) <0.001
0.44 (0.27-0.72) <0.001
0.71 (0.43-1.18) 0.100
0.20 (0.14-0.61) <0.001
0.49 (0.24-1.01) 0.030
0.29 (0.17-0.51) <0.001
0.46 (0.27-0.77) 0.004
0.84 (0.47-1.5) 0.568
0.31 (0.11-0.84) 0.022
1.18 (0.44-3.15) 0.735
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negative patients (36/330, 32.7%) compared to HIV-
positives (47/330, 21,4%, p=0.01). However, when patients
on CTX chemoprophylaxis and/or ART were excluded, the
proportion of HIV-infected patients admitted for clinical
malaria was similar to that of HIV-negative subjects (42/
238, 32.8%, p=0.54).
Clinical and laboratory characteristics of the 83 patients
with clinical malaria were then compared in the HIV-
positive and HIV-negative groups (Table 3). Overall, se-
vere malaria seemed to be more common in the group of
HIV-positive patients (61.7%) compared to HIV-negatives
(47.2%) but this difference was not statistically significant
(p=0.13). Among the reported symptoms and signs, a
higher frequency of dyspnea (p=0.09) and diarrhea
(p=0.03) was observed among HIV-positive patients, while
headaches (p=0.03) and hypotension (p=0.05) were more
frequently found in HIV-negative patients. No differences
between the two groups were reported regarding nausea,
vomiting, jaundice, cough, weight loss and neurological
symptoms, including convulsions and coma. Fever was
not included in this list because it was considered a cri-
teria for defining clinical malaria in both groups. Further-
more, no differences were observed between the two
groups regarding percentage of patients for whom a
hepato-splenomegaly was reported.Table 3 Clinical characteristics and blood parameters in 83 pa
serology
HIV positive
No. (%)
Patients with severe malaria 29 (61.7%)
Clinical symptoms and signs
Headache 35 (74.5%)
Jaundice 10 (21.3%)
Cough 17 (36.2%)
Dyspnea 15 (31.9%)
Nausea 33 (70.2%)
Vomiting 33 (70.2%)
Diarrhoea 19 (40.4%)
Hypotension 0
Convulsions and/or coma 7 (14.9)
Weight loss 20 (42.6%)
Hepatomegaly 22 (46.8%)
Splenomegaly 22 (46.8%)
Blood parameters mean±SD
WBC/mmc 7.7±2.5
Hbmg/dl 9.9 ±2.8
PLT (x100.000/mmc) 188.4±120.9
Glycaemia (mmol/L)* 4.8±1.5
*data available only for 17 patients.The following laboratory parameters were available for
comparison: white blood cells (WBC), haemoglobin (Hb),
platelets (PLT) and glycaemia. The total number of WBC
was comparable betweenHIV-positive andnegativepatients
with malaria (mean 7.7±2.5 versus 7.7±3.7 cells/mmc, re-
spectively, p=0.2). On the contrary, a lower Hb level was
observed in the group of HIV-positives (9.9±2.8mg/dl)
compared to HIV-negative subjects (12.1±2.8mg/dl)
(p=0.003) along with an inferior platelet count (188.4
±120.9 cells/mmc versus 218.8±126.1 cells/mmc, re-
spectively, p=0.07). A lower level of Hb (8.4±3.7 vs 9.6
±2.8g/dl, p=0.006) was observed in the group of HIV-
positive patients treated with ART, along with an higher
prevalence of both severe (Hb<7g/dl) and moderate
(Hb<10g/dl) anemia. A total of 6/12 patients treated by
AZT presented moderate anemia.
Glycaemia was measured only in a small percentage of
malaria patients (17/83); a lower level of glucose was
recorded among HIV patients (4.8±1.5mmol/L versus
7.4±1.6, p=0.01).
Discussion
Mozambique is a country with stable P. falciparum
transmission, where malaria-related morbidity and mor-
tality is still quite frequent, with more than four million
cases and 4,000 attributed deaths reported each year [9].tients diagnosed with clinical malaria according to HIV
HIV negative p value
No. (%)
17 (47.2%) 0.13
33 (91-7%) 0.03
5 (13.9%) 0.28
10 (27.8%) 0.28
6 (16.7%) 0.09
26 (72.2%) 0.51
26 (72.2%) 0.40
7 (19.4%) 0.03
6 (16.7%) 0.05
6 (16.7) 0.52
11 (30.6%) 0.18
14 (38.8%) 0.30
11 (30.6%) 0.10
mean±SD
7.7±3.7 0.25
12.1±2.8 0.003
218.8±126.1 0.07
7.4±1.6 0.02
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for malaria; in fact, transmission is seasonal, mainly be-
tween November and July with peaks from December to
April in the Central region of the country.
At the same time, the proportion of individuals coex-
isting with HIV in the whole population is about 16%
according to the last epidemiological survey in 2007
[7], with the Northern and Central regions presenting
a higher prevalence compared to the Southern part of
the country. In particular, the Sofala province shows a
prevalence rate between 17% and 33%, with the highest
peaks involving urban areas. Among these, Beira, which
is the 2nd largest city in Mozambique (population of
more than 400,000 inhabitants), has one of the highest
adult HIV seroprevalence rates in the country. The na-
tional survey based on sentinel posts throughout the
country shows that the rate of HIV prevalence mea-
sured in pregnant women reached a peak of 36% in
Beira in 2002, stabilizing around 29% in the last report
in 2007 [7] while the 2009 WHO report gives a range
between 25% and 39.9% for Beira [8]. This rate is extra
ordinarly high and is probably due to geographical
and historical reasons linked to its role as a key com-
mercial harbor on the Indian Ocean, thus probably
favouring a high sexual promiscuity. This is reflected
in the impressive HIV prevalence (66.7%) in patients
hospitalized in the Internal medicine Clinic of the
Central Hospital of Beira serving a wide area of Central
Mozambique.
Only a few studies have evaluated the epidemio-
logical and clinical aspects concerning concurrent HIV
and malaria in this country [10] and, none in the
above-mentioned area. In particular, data are lacking
on the reciprocal influence of the two infections on
the morbidity of the Mozambican population following
the contemporary introduction in 2004 of both ART
for HIV infection and a new artemisinin-based treat-
ment for malaria.
Malaria, according to our analysis, is still the most
frequent cause of adult admissions to Internal Medicine
wards in Mozambique (>25% of all motives for hospi-
talization). However, when evaluating patients based on
their HIV serological status, results show that, although
HIV-infected patients are considered a high risk group
for malaria, malaria is not the most frequent diagnosis
in this patient group, and the prevalence of both mal-
aria infection and clinical malaria is lower among HIV-
infected patients (26% and 21%, respectively) than
among HIV-negatives (33% and 32%, respectively). This
might imply at least two different explanations: The
first is that, naturally, the prevalence of malaria infec-
tion in hospitalized patients does not directly reflect the
disease distribution throughout the entire population,
due to the greater number of pathologies, especiallyAIDS-related opportunistic infections, which could
require hospitalization in HIV-infected individuals
compared to HIV-negatives. In fact, a previous study
performed in Maputo, Mozambique, has already evi-
denced that the fraction of febrile illness attributable
to malaria is lower in HIV-positive adults than in
HIV-negatives [10]. However, a second explanation is
possible as a statistically significant and independent as-
sociation between CTX use and decreased risk of mal-
aria infection was observed, while, on the contrary, the
malaria distribution did not differ between untreated-
HIV-positive and HIV-negative patients. These results
are not surprising as the protective effect of cotrimoxa-
zole on parasite infection has been well-documented in
clinical trials in children [11], pregnant women [12] and
adults [6,13]. The present study confirms this protective
effect also in the “real word” scenario of an African urban
hospital, outside the selected conditions of a randomized
clinical trial.
The effect of anti-virals on malaria parasitaemia is still
questionable [4,5], and only protease inhibitors are cur-
rently considered to provide a proven anti-malarial effi-
cacy [14-19], even if in a recent study, a low anti genaemia
was demonstrated for suppressed HIV-infected patients
treated with ART and CTX for long periods [20]. In this
study it was not possible to individuate aviremic patients,
because neither viral load nor CD4 count were available;
however, the median duration of ART was only four
months and 77% of patients were classified as WHO stage
III-IV. The majority (67/69) of treated patients were on
NNRTIs; an association between the use of antiretrovirals
and lower risk of malaria was observed at univariate ana-
lysis but it most likely depended on the protective effect of
CTX rather than on the direct impact of ART, as statis-
tical significance was not confirmed with multivariate ana-
lysis. Hence, further studies directly assessing this topic
are required to validate this association.
A wider implementation of prophylaxis for HIV-
infected subjects in sub-Saharan Africa in future years
might, therefore, substantially reduce the burden of mal-
aria infection and consequently its morbidity in these
patients. Moreover, it also appears that the problem of a
greater access to HIV testing is the fundamental issue. In
fact, the extensive use of HIV testing in the hospital
demonstrates that more than one-half of HIV-positive
subjects were unaware of their seropositivity before
hospitalization. Thus, among HIV-infected patients, only
31% and 35% were already receiving antiretroviral therapy
and/or chemoprophylaxis for opportunistic infections, re-
spectively. Moreover, low rates of regimen switches were
described (only two patients were on a second line regi-
men): this is not surprising as the average ART-treatment
time in the present study was only four months; moreover
the lack of testing for viral load renders it difficult to
Saracino et al. Malaria Journal 2012, 11:241 Page 7 of 8
http://www.malariajournal.com/content/11/1/241early individuate therapy failure. These data are consist-
ent with the study of Auld et al. [21] on ART imple-
mentation in Mozambique, even if in disagreement
regarding the rate of prescription of CTX, which was
lower in their survey compared to ours.
Despite the low frequency of infection and clinical mal-
aria diagnosed in HIV-positive patients, no statically signifi-
cant differences were noted either in parasitaemia or in
occurrence of severe malaria, but this study presents two
limitations: the use of a semi quantitative method for meas-
uring parasitaemia whose low accuracy does not permit us
to deduct any definite conclusions, and the lack of many la-
boratory parameters which render incomplete our criteria
for classification of complicated malaria. However, a trend
toward a more severe presentation characterized the HIV-
malaria co-infection, with more frequent symptoms, such
as dyspnea and diarrhea, occurring in the HIV population.
Remarkably, anaemia was significantly associated with
HIV-infection in malaria patients, and a trend towards a
lower platelet number was also observed in co-infected
individuals. Cytopenia of all major blood cell lines have
been recognized in patients with chronic HIV since the be-
ginning of the epidemic [22] and its incidence directly cor-
relates with the degree of immuno suppression, although
isolated abnormalities, particularly thrombocytopenia, may
be encountered also as the initial presentation of HIV infec-
tion. In this analysis, anaemia was also associated with use
of ART. ART has been demonstrated to improve preexist-
ing anemia after use for at least 6 months [23], but the me-
dian length of therapy in our series was only four months.
Therefore, the association between anaemia and ART prob-
ably only indicates a more advanced stage of HIV infection
in treated patients. These results confirm and extend previ-
ous observations [24] emphasizing the need to avoid the
dual infection, thus limiting hematological complications in
these patients.
Lastly, the study was carried out in a 3rd level hospital
where blood slides for confirming malaria have been largely
used for some years; for the purposes of the analysis, MBSs
were utilized for all hospitalized patients in Internal medi-
cine, thus permitting us to reject about 10% of the pre-
sumptive malaria diagnoses; contrary to previous
observations [10], an overestimation of malaria in HIV-
positives when compared to HIV-negatives was not noted.
The results of RDT were comparable to those of MBS in
both HIV-infected and non-infected patients, independ-
ently of simultaneous treatment with ART; RDT use did
not seem to provide an added value for correct diagnosis in
patients already submitted to MBS, but the high sensitivity
(94%) and specificity (96%) obtained in our survey con-
firmed that they are suitable in all fields in which MBS is
not feasible and accuracy cannot be assured due to lack
of expertise.Conclusions
In conclusion, malaria infection appears to be rare
in HIV-infected individuals when treated with a
cotrimoxazole-based chemoprophylaxis for opportunistic
infections, even in an area with a high co-infection rate
such as Mozambique; therefore, a more extensive use of
CTX for opportunistic infections in malaria endemic
countries is warranted. No independent effect of NNRTIs
on malaria infection was evidenced in our study. When
HIV and malaria co-infection occurs, a high complication
risk, particularly anaemia, should be considered.
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